Anal Fissure News and Research RSS Feed - Anal Fissure News and Research

Apremilast drug shows promise for Behcet's ulcers

Apremilast drug shows promise for Behcet's ulcers

Apremilast, an orally available small molecule modulating several inflammatory pathways, which is pending approval by the United States Food and Drug Administration, is showing promise in the treatment of mouth and genital ulcers in people with Behcet's syndrome, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in San Diego. [More]
Exclusion diet boosts anal fissure healing

Exclusion diet boosts anal fissure healing

Research published in the American Journal of Gastroenterology shows that an exclusion diet combined with medical treatment can increase healing rates in patients with chronic anal fissure who have been referred for surgery. [More]
Study supports sphincter-saving surgery

Study supports sphincter-saving surgery

Fissurectomy results in high levels of healing and low rates of anal incontinence, show the results of the largest ever prospective study of the technique. [More]
FDA approves ProStrakan's Rectiv for pain associated with anal fissures

FDA approves ProStrakan's Rectiv for pain associated with anal fissures

ProStrakan Group plc, a subsidiary of Kyowa Hakko Kirin Co. Ltd., and an international specialty pharmaceutical company, today announces that it has received approval from the U.S. Food and Drug Administration (FDA) for Rectiv™ (nitroglycerin) Ointment 0.4 % for the treatment of moderate to severe pain associated with chronic anal fissures. [More]
Botox - other applications

Botox - other applications

While botulinum toxin A, or BTXA, is widely known for its use in dermatology and aesthetic medicine, a review article in the Journal of Cosmetic Dermatology explores the drug’s other successful applications. [More]

FDA issues not approvable letter to Cellegy Pharmaceuticals

Cellegy Pharmaceuticals has announced receipt of a communication from the U.S. Food and Drug Administration in the form of a Not Approvable Letter for its product Cellegesic(TM) (nitroglycerin ointment). [More]